Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
NanoSmart Pharmaceuticals announced that the FDA has granted Orphan Drug designation to its antinuclear antibody (ANA) conjugated liposomal doxorubicin intended to treat Ewing’s sarcoma, with potential expansion to other indications.
RELATED: To Reduce Cancer Risk, Focus Should be on Lifestyle Changes
NanoSmart is developing an improved, ANA-targeted, liposomal formulation of doxorubicin that focuses drug delivery at the tumor site. Non-clinical testing has revealed the potential to improve the safety and efficacy of liposomal doxorubicin. Because ANA conjugation enables the drug to bind to areas of necrosis that are present in solid tumors, NanoSmart anticipates expanding into additional pediatric indications.
For more information visit NanoSmartPharm.com.
